Funding
Curetis AG has raised €18.5M from a consortium of life-science venture capital funds, enabling the company to complete development of molecular diagnostics for testing for severe infectious diseases.
The new €18.5 million comes from an international consortium, including the existing investor aeris CAPITAL, which seeded Curetis with €1.4 million in 2008. New syndicate members are Life Sciences Partners, BioMedPartners, the ERP-Startfonds of the KfW Bankengruppe and MedVenture Partners GmbH.
Curetis is developing universal molecular diagnostics, initially focusing on severe bacterial infections such as pneumonia. Globally, over 25 million people are diagnosed each year with pneumonia and there is a need for faster diagnoses, allowing the infection to be treated in a timely and cost-effective manner.
“The fact that we could close this significant round with such a strong syndicate in today’s stressed financial markets is a testament to our investors’ confidence in Curetis’ potential,” said the joint managing directors of Curetis, Johannes Bacher and Andreas Boos.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
